Of mice and men—shedding new light on IL-13 activity in IBD (original) (raw)

IBD

Nature Reviews Gastroenterology & Hepatology volume 8, pages 128–129 (2011)Cite this article

Subjects

A recent study in a mouse model of colitis has demonstrated that interleukin (IL)-13, through inhibition of the mixed type 1 and type 17 T-helper cell inflammatory response, has a protective effect. The decoy receptor IL-13Rα2 inhibits this protective effect, suggesting blockade of IL-13Rα2 as a potential therapy for patients with IBD.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: The functional role of IL-13 in intestinal inflammation.

References

  1. Fuss, I. J. et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12p40 monoclonal antibody. Inflamm. Bowel Dis. 12, 9–15 (2006).
    Article PubMed Google Scholar
  2. Zhang, Z., Zheng, M., Bindas, J., Schwarzenberger, P. & Kolls, J. K. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12, 382–388 (2006).
    Article PubMed Google Scholar
  3. Fuss, I. J. et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize and atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113, 1490–1497 (2004).
    Article CAS PubMed PubMed Central Google Scholar
  4. Murphy, K. M. & Stockinger, B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 11, 674–680 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  5. Wilson, M. S. et al. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity. Gastroenterology 140, 254–264 (2011).
    Article CAS PubMed Google Scholar
  6. Heller, F., Fuss, I. J., Nieuwenhuis, E. E., Blumberg, R. S. & Strober, W. Oxazalone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17, 629–638 (2002).
    Article CAS PubMed Google Scholar
  7. Fichtner-Feigl, S. et al. IL-13 signaling via IL-13Rα2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 135, 2003–2013 (2008).
    Article CAS PubMed Google Scholar
  8. Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550–564 (2005).
    Article CAS PubMed Google Scholar
  9. Mandal, D. & Levine, A. D. Elevated IL-13Rα2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm. Bowel Dis. 16, 753–764 (2010).
    Article PubMed Google Scholar
  10. Arijs, I. et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58, 1612–1619 (2009).
    Article CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. IBD Center, IRCCS Humanitas, Via Manzoni 56, Rozzano, 20089, Milan, Italy
    Silvio Danese

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

About this article

Cite this article

Danese, S. Of mice and men—shedding new light on IL-13 activity in IBD.Nat Rev Gastroenterol Hepatol 8, 128–129 (2011). https://doi.org/10.1038/nrgastro.2011.17

Download citation